H. Farmer, N. Mccabe, C. J. Lord, A. Tutt, D. A. Johnson et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, pp.917-938, 2005.

H. E. Bryant, N. Schultz, H. D. Thomas, K. M. Parker, D. Flower et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, vol.434, pp.913-920, 2005.

J. M. Brown, D. J. Carlson, and D. J. Brenner, The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?, Int J Radiat Oncol Biol Phys, vol.88, pp.254-62, 2014.

W. Y. Mansour, T. Rhein, and J. Dahm-daphi, The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies, Nucleic Acids Res, vol.38, pp.6065-77, 2010.

N. Schultz, E. Lopez, N. Saleh-gohari, and T. Helleday, Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination, Nucleic Acids Res, vol.31, pp.4959-64, 2003.
DOI : 10.1093/nar/gkg703
URL : https://academic.oup.com/nar/article-pdf/31/17/4959/4023856/gkg703.pdf

Q. Cheng, N. Barboule, P. Frit, D. Gomez, O. Bombarde et al., Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks, Nucleic Acids Res, vol.39, pp.9605-9624, 2011.

G. Gradwohl, J. Murcia, . De, M. Molinete, F. Simonin et al., The second zincfinger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA, Proc Natl Acad Sci, vol.87, pp.2990-2994, 1990.

M. Ikejima, S. Noguchi, R. Yamashita, T. Ogura, T. Sugimura et al., The zinc fingers of human poly(ADPribose) polymerase are differentially required for the recognition of DNA breaks and nicks and the consequent enzyme activation. Other structures recognize intact DNA, J Biol Chem, vol.265, pp.21907-21920, 1990.

M. Li and X. Yu, The Role of Poly(ADP-ribosyl)ation in DNA Damage Response and Cancer Chemotherapy, Oncogene, vol.34, pp.3349-56, 2015.

Y. Saintigny, F. Delacôte, G. Varès, F. Petitot, S. Lambert et al., Characterization of homologous recombination induced by replication inhibition in mammalian cells, EMBO J, vol.20, pp.3861-70, 2001.

C. E. Ström, F. Johansson, M. Uhlén, C. Szigyarto, K. Erixon et al., ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate, Nucleic Acids Res, vol.39, pp.3166-75, 2011.

A. Cerrato, F. Morra, and A. Celetti, Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic, J Exp Clin Cancer Res CR, vol.35, p.179, 2016.

H. E. Bryant, E. Petermann, N. Schultz, A. S. Jemth, O. Loseva et al., PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination, EMBO J, vol.28, pp.2601-2616, 2009.
DOI : 10.1038/emboj.2009.206
URL : http://emboj.embopress.org/content/28/17/2601.full.pdf

A. Grabarz, A. Barascu, J. Guirouilh-barbat, and B. S. Lopez, Initiation of DNA double strand break repair: signaling and single-stranded resection dictate the choice between homologous recombination, non-homologous end-joining and alternative end-joining, Am J Cancer Res, vol.2, pp.249-68, 2012.

G. Noël, C. Godon, M. Fernet, N. Giocanti, F. Mégnin-chanet et al., Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis, Mol Cancer Ther, vol.5, pp.564-74, 2006.

F. A. Dungey, D. A. Löser, and A. J. Chalmers, Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential, Int J Radiat Oncol Biol Phys, vol.72, pp.1188-97, 2008.

A. J. Gottschalk, G. Timinszky, S. E. Kong, J. J. Cai, Y. Swanson et al., Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler, Proc Natl Acad Sci USA, vol.106, pp.13770-13774, 2009.
DOI : 10.1073/pnas.0906920106
URL : http://www.pnas.org/content/106/33/13770.full.pdf

D. Ahel, Z. Horejsí, N. Wiechens, S. E. Polo, E. Garcia-wilson et al., Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1, Science, vol.325, pp.1240-1243, 2009.

A. E. Gorbalenya, E. V. Koonin, A. P. Donchenko, and V. M. Blinov, Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes, Nucleic Acids Res, vol.17, pp.4713-4743, 1989.

M. Ali, B. A. Telfer, C. Mccrudden, M. O'rourke, H. D. Thomas et al., Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?, Clin Cancer Res Off J Am Assoc Cancer Res, vol.15, pp.6106-6118, 2009.

J. M. Brown and W. R. Wilson, Exploiting tumour hypoxia in cancer treatment, Nat Rev Cancer, vol.4, pp.437-484, 2004.
DOI : 10.1038/nrc1367

B. Hong, J. Kim, H. Jeong, S. Bok, Y. Kim et al., Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy, Radiat Oncol J, vol.34, pp.239-288, 2016.
DOI : 10.3857/roj.2016.02012
URL : https://doi.org/10.3857/roj.2016.02012

J. M. Brown and W. R. Wilson, Exploiting tumour hypoxia in cancer treatment, Nat Rev Cancer, vol.4, pp.437-484, 2004.
DOI : 10.1038/nrc1367

L. A. Loeb, Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences, Cancer Res, vol.76, pp.2057-2066, 2016.
DOI : 10.1158/0008-5472.can-16-0794
URL : http://cancerres.aacrjournals.org/content/76/8/2057.full.pdf

R. G. Bristow and R. P. Hill, Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability, Nat Rev Cancer, vol.8, pp.180-92, 2008.

N. Chan, I. M. Pires, Z. Bencokova, C. Coackley, K. R. Luoto et al., Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment, Cancer Res, vol.70, pp.8045-54, 2010.

T. M. Pawlik and K. Keyomarsi, Role of cell cycle in mediating sensitivity to radiotherapy, Int J Radiat Oncol Biol Phys, vol.59, pp.928-970, 2004.

J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote et al., Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, vol.15, issue.14, pp.70228-70229, 2014.

Y. Drew, J. Ledermann, G. Hall, D. Rea, R. Glasspool et al., Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer, Br J Cancer, vol.114, pp.723-753, 2016.

M. R. Mirza, B. J. Monk, J. Herrstedt, A. M. Oza, S. Mahner et al., Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, N Engl J Med, vol.375, pp.2154-64, 2016.
DOI : 10.1097/ogx.0000000000000404
URL : http://discovery.ucl.ac.uk/1524667/1/Ledermann_nejmoa1611310.pdf

S. M. Domchek, C. Aghajanian, R. Shapira-frommer, R. K. Schmutzler, M. W. Audeh et al., Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

, Gynecol Oncol, vol.140, pp.199-203, 2016.

T. Helleday, The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings, Mol Oncol, vol.5, pp.387-93, 2011.

P. S. Kedar, D. F. Stefanick, J. K. Horton, and S. H. Wilson, Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts, Mol Cancer Res MCR, vol.10, pp.360-368, 2012.
DOI : 10.1158/1541-7786.mcr-11-0477
URL : http://mcr.aacrjournals.org/content/10/3/360.full.pdf

D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and P. Group, Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement, J Clin Epidemiol, vol.62, pp.1006-1018, 2009.
DOI : 10.1016/j.ijsu.2010.02.007
URL : https://doi.org/10.1016/j.ijsu.2010.02.007

A. Chalmers, P. Johnston, M. Woodcock, M. Joiner, and B. Marples, PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation, Int J Radiat Oncol Biol Phys, vol.58, pp.410-419, 2004.

A. L. Russo, H. Kwon, W. E. Burgan, D. Carter, K. Beam et al., In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016, Clin Cancer Res, vol.15, pp.607-619, 2009.

D. G. Van-vuurden, E. Hulleman, O. Meijer, L. E. Wedekind, M. Kool et al., PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation, Oncotarget, vol.2, pp.984-96, 2011.

L. Barazzuol, J. R. Burnet, N. G. Meira, L. B. Jeynes, J. Kirkby et al., Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma, Radiat Oncol Lond Engl, vol.8, p.65, 2013.

D. L. Nile, C. Rae, I. J. Hyndman, M. N. Gaze, and R. J. Mairs, An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma, BMC Cancer, vol.16, p.621, 2016.

T. R. Jue, K. Nozue, A. J. Lester, S. Joshi, L. Schroder et al., Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma, J Transl Med, vol.15, p.61, 2017.

S. U. Ahmed, R. Carruthers, L. Gilmour, S. Yildirim, C. Watts et al., Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells, Cancer Res, vol.75, pp.4416-4444, 2015.

Y. Chornenkyy, S. Agnihotri, M. Yu, P. Buczkowicz, P. Rakopoulos et al., Poly-ADPRibose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma, Mol Cancer Ther, vol.14, pp.2560-2568, 2015.

S. Mueller, S. Bhargava, A. M. Molinaro, X. Yang, I. Kolkowitz et al.,

K. K. Matthay, D. A. Haas-kogan, and . Poly, ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma, Anticancer Res, vol.33, pp.755-62, 2013.

L. R. Kelland, L. Burgess, and G. G. Steel, Differential radiosensitization by the poly(ADP-ribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity, Int J Radiat Oncol Biol Phys, vol.14, pp.1239-1285, 1988.

L. Kleinberg, J. G. Supko, T. Mikkelsen, J. O. Blakeley, G. Stevens et al., Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data, J Clin Oncol

M. P. Mehta, W. J. Curran, D. Wang, F. Wang, L. Kleinberg et al., Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases, J Clin Oncol, p.2017, 2012.

P. Baxter, J. Su, X. Li, A. O. Thomas, C. Billups et al., Ept-15a phase1/2 clinical trial of veliparib (abt-888) and radiation followed by maintenance therapy with veliparib and temozolomide (tmz) in patients with newly diagnosed diffuse intrinsic pontine glioma (dipg): a pediatric brain tumor consortium interim report of phase ii study, Neuro-Oncol, vol.18, pp.27-27, 2016.

P. Chabot, T. Hsia, J. Ryu, V. Gorbunova, C. Belda-iniesta et al., Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study, J Neurooncol, vol.131, pp.105-120, 2017.

A. Galia, A. E. Calogero, R. Condorelli, F. Fraggetta, L. Corte et al., PARP-1 protein expression in glioblastoma multiforme, Eur J Histochem EJH, vol.56, 2012.

S. Bao, Q. Wu, R. E. Mclendon, Y. Hao, Q. Shi et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.444, pp.756-60, 2006.

M. Venere, P. Hamerlik, Q. Wu, R. D. Rasmussen, L. A. Song et al., Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells, Cell Death Differ, vol.21, pp.258-69, 2014.

R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-96, 2005.

S. Miknyoczki, H. Chang, J. Grobelny, S. Pritchard, C. Worrell et al., The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity, Mol Cancer Ther, vol.6, pp.2290-302, 2007.

S. J. Miknyoczki, S. Jones-bolin, S. Pritchard, K. Hunter, H. Zhao et al., Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor, Mol Cancer Ther, vol.2, pp.371-82, 2003.

L. Tentori, L. Ricci-vitiani, A. Muzi, F. Ciccarone, F. Pelacchi et al.,

, polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide, BMC Cancer, vol.14, p.151, 2014.

R. K. Balvers, M. Lamfers, J. J. Kloezeman, A. Kleijn, B. Pont et al., ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells, J Transl Med, vol.13, p.74, 2015.

S. K. Gupta, A. C. Mladek, B. L. Carlson, F. Boakye-agyeman, K. K. Bakken et al., Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomidesensitive versus-resistant glioblastoma multiforme xenografts, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, pp.3730-3771, 2014.

S. K. Gupta, S. H. Kizilbash, B. L. Carlson, A. C. Mladek, F. Boakyeagyeman et al., Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated TemozolomideSensitizing Therapy of Glioblastoma, J Natl Cancer Inst, vol.108, 2016.

B. Mcellin, C. V. Camacho, B. Mukherjee, B. Hahm, N. Tomimatsu et al., PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors, Cancer Res, vol.70, pp.5457-64, 2010.

C. K. Donawho, Y. Luo, Y. Luo, T. D. Penning, J. L. Bauch et al.,

L. E. Dillehay, D. C. Ferguson, N. S. Ghoreishi-haack, and D. R. Grimm, ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models, Clin Cancer Res Off J Am Assoc Cancer Res, vol.13, pp.2728-2765, 2007.

K. M. Murphy, K. A. Brune, C. Griffin, J. E. Sollenberger, G. M. Petersen et al., Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%, Cancer Res, vol.62, pp.3789-93, 2002.

L. Porcelli, A. E. Quatrale, P. Mantuano, M. G. Leo, N. Silvestris et al., Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity, Mol Oncol, vol.7, pp.308-330, 2013.

T. Hirai, S. Saito, H. Fujimori, K. Matsushita, T. Nishio et al., Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells, Biochem Biophys Res Commun, vol.478, pp.234-274, 2016.

D. Karnak, C. G. Engelke, L. A. Parsels, T. Kausar, D. Wei et al., Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, pp.5085-96, 2014.

S. Vance, E. Liu, L. Zhao, J. D. Parsels, L. A. Parsels et al., Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1, Cell Cycle Georget Tex, vol.10, pp.4321-4330, 2011.

T. Hirai, H. Shirai, H. Fujimori, R. Okayasu, K. Sasai et al., Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation, Cancer Sci, vol.103, pp.1045-50, 2012.

, ESTRO 36 Abstract Book, 2017.

I. Lohse, R. Kumareswaran, P. Cao, B. Pitcher, S. Gallinger et al., Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts, PLoS ONE, p.2017, 2016.

, , vol.11

R. Tuli, N. N. Nissen, A. Annamalai, D. Hoffman, M. Bryant et al., Phase I study of veliparib with gemcitabine and radiation therapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer, J Clin Oncol, vol.34, pp.487-487, 2016.

H. L. Kindler, G. Y. Locker, H. Mann, and T. Golan, POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy, J Clin Oncol

J. W. Shelton, T. V. Waxweiler, J. Landry, H. Gao, Y. Xu et al., In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells, Int J Radiat Oncol Biol Phys, vol.86, pp.469-76, 2013.

M. Michael, M. F. Mulcahy, D. A. Deming, H. Vaghefi, G. S. Jameson et al., Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer (LARC): Final results of a phase Ib study, J Clin Oncol, vol.33, 2015.

C. R. Calabrese, R. Almassy, S. Barton, M. A. Batey, A. H. Calvert et al., Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361, JNCI J Natl Cancer Inst, vol.96, pp.56-67, 2004.

K. Miura, K. Sakata, M. Someya, Y. Matsumoto, H. Matsumoto et al., The combination of olaparib and camptothecin for effective radiosensitization, Radiat Oncol Lond Engl, vol.7, 2012.

M. Alotaibi, K. Sharma, T. Saleh, L. F. Povirk, E. A. Hendrickson et al., Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells, Radiat Res, vol.185, pp.229-274, 2016.

K. Hastak, S. Bhutra, R. Parry, and J. M. Ford, Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers, Oncotarget, vol.8, pp.26344-55, 2017.

C. Guillot, V. Favaudon, Z. Herceg, C. Sagne, S. Sauvaigo et al., PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models. BMC Cancer, vol.14, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01122364

B. G. Czito, D. A. Deming, G. S. Jameson, M. F. Mulcahy, H. Vaghefi et al., Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study, Lancet Gastroenterol Hepatol, vol.2, pp.30012-30014, 2017.

K. A. Reiss, J. M. Herman, D. Armstrong, M. Zahurak, A. Fyles et al., A final report of

T. J. Strom, A. O. Naghavi, A. M. Trotti, J. Russell, J. A. Kish et al., Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ? 70 years, J Geriatr Oncol, vol.8, pp.50-55, 2017.

J. D. Güster, S. V. Weissleder, C. Busch, M. Kriegs, C. Petersen et al., The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.113, pp.345-51, 2014.

C. M. Nickson, P. Moori, R. J. Carter, C. P. Rubbi, and J. L. Parsons, Misregulation of DNA damage repair pathways in HPVpositive head and neck squamous cell carcinoma contributes to cellular radiosensitivity, Oncotarget, vol.8, pp.29963-75, 2017.

S. Wurster, F. Hennes, A. C. Parplys, J. I. Seelbach, W. Y. Mansour et al., PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response, Oncotarget, vol.7, pp.9732-9773, 2016.

S. Nowsheen, J. A. Bonner, and E. S. Yang, The poly(ADPRibose) polymerase inhibitor ABT-888 reduces radiationinduced nuclear EGFR and augments head and neck tumor response to radiotherapy, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.99, pp.331-339, 2011.

K. Dittmann, C. Mayer, B. Fehrenbacher, M. Schaller, U. Raju et al., Radiationinduced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase, J Biol Chem, vol.280, pp.31182-31191, 2005.

D. Raben, D. Bowles, T. Waxweiler, S. Karam, and A. Jimeno, SP0298: Phase I Results of PARPi (Olaparib) + RT + Cetuximab in LAHNSCC, Radiother Oncol, vol.119, issue.16, p.31547, 2016.

K. Khan, K. Araki, D. Wang, G. Li, X. Li et al., Head and neck cancer radiosensitization by the novel poly(ADPribose) polymerase inhibitor GPI-15427, Head Neck, vol.32, pp.381-91, 2010.

C. Verhagen, R. De-haan, F. Hageman, T. Oostendorp, A. Carli et al., Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.116, pp.358-65, 2015.

J. Chow, W. Y. Man, M. Mao, H. Chen, F. Cheung et al., PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy, Mol Cancer Ther, vol.12, pp.2517-2545, 2013.

Z. R. Zhou, X. D. Zhu, W. Zhao, S. Qu, F. Su et al., Poly(ADP-ribose) polymerase-1 regulates the mechanism of irradiation-induced CNE-2 human nasopharyngeal carcinoma cell autophagy and inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells, Oncol Rep, vol.29, pp.2498-506, 2013.

J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop et al., DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer, N Engl J Med, vol.373, pp.1697-708, 2015.

M. A. Rubin, C. A. Maher, and A. M. Chinnaiyan, Common gene rearrangements in prostate cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, pp.3659-68, 2011.

P. Chatterjee, G. S. Choudhary, T. Alswillah, X. Xiong, W. D. Heston et al., The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition, Mol Cancer Ther, vol.14, pp.1896-906, 2015.

C. Gani, C. Coackley, R. Kumareswaran, C. Schütze, M. Krause et al., In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.116, pp.486-94, 2015.

A. Schlicker, P. Peschke, A. Bürkle, E. W. Hahn, and J. H. Kim, 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADPribose) polymerase and radiation sensitizer, Int J Radiat Biol, vol.75, pp.91-100, 1999.

S. K. Liu, C. Coackley, M. Krause, F. Jalali, N. Chan et al., A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.88, pp.258-68, 2008.

J. C. Barreto-andrade, E. V. Efimova, H. J. Mauceri, M. A. Beckett, H. G. Sutton et al., Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation, Mol Cancer Ther, vol.10, pp.1185-93, 2011.

P. Chatterjee, G. S. Choudhary, A. Sharma, K. Singh, W. D. Heston et al., PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells, PLoS ONE, vol.8, 2013.
DOI : 10.1371/journal.pone.0060408
URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0060408&type=printable

S. Han, J. C. Brenner, A. Sabolch, W. Jackson, C. Speers et al., Targeted radiosensitization of ETS fusionpositive prostate cancer through PARP1 inhibition, Neoplasia NYN, vol.15, pp.1207-1224, 2013.

K. A. Bridges, C. Toniatti, C. A. Buser, H. Liu, T. A. Buchholz et al., Niraparib (MK-4827), a novel poly(ADPRibose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells, Oncotarget, vol.5, pp.5076-86, 2014.

A. Kötter, K. Cornils, K. Borgmann, J. Dahm-daphi, C. Petersen et al., Inhibition of PARP1dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells, Mol Oncol, vol.8, pp.1616-1641, 2014.

C. Rae and R. J. Mairs, Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells, Int J Radiat Biol, vol.93, pp.194-203, 2017.

Y. Jiang, T. Verbiest, A. M. Devery, S. M. Bokobza, A. M. Weber et al., Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality, Int J Radiat Oncol Biol Phys, vol.95, pp.772-81, 2016.

R. Cardnell, Y. Feng, L. Diao, Y. Fan, F. Masrorpour et al., Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.19, 2013.

T. K. Owonikoko, G. Zhang, X. Deng, M. R. Rossi, J. M. Switchenko et al., ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer, Cancer Med, vol.3, pp.1579-94, 2014.

J. M. Albert, C. Cao, K. W. Kim, C. D. Willey, L. Geng et al., Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models, Clin Cancer Res Off J Am Assoc Cancer Res, vol.13, pp.3033-3075, 2007.

P. J. Thraves, K. L. Mossman, D. T. Frazier, and A. Dritschilo, Inhibition of potentially lethal radiation damage repair in normal and neoplastic human cells by 3-aminobenzamide: an inhibitor of poly(ADP-ribosylation), Int J Radiat Oncol Biol Phys, vol.12, pp.1541-1546, 1986.

J. M. Senra, B. A. Telfer, K. E. Cherry, C. M. Mccrudden, D. G. Hirst et al., Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft, Mol Cancer Ther, vol.10, pp.1949-58, 2011.

L. Wang, K. A. Mason, K. K. Ang, T. Buchholz, D. Valdecanas et al., MK4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation, Invest New Drugs, vol.30, pp.2113-2133, 2012.

F. Y. Feng, C. Speers, M. Liu, W. C. Jackson, D. Moon et al., Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer, Breast Cancer Res Treat, vol.147, pp.81-94, 2014.

E. V. Efimova, H. J. Mauceri, D. W. Golden, E. Labay, V. P. Bindokas et al., Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors, Cancer Res, vol.70, pp.6277-82, 2010.

R. Jagsi, K. A. Griffith, J. R. Bellon, W. A. Woodward, J. K. Horton et al., TBCRC 024 Initial Results: A Multicenter Phase 1 Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer, Int J Radiat Oncol ? Biol ? Phys, vol.93, 2015.

L. R. Kelland and K. S. Tonkin, The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.15, pp.363-372, 1989.

H. Lee, C. Yoon, B. Schmidt, D. J. Park, A. Y. Zhang et al., Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage, Mol Cancer Ther, vol.12, pp.2591-600, 2013.
DOI : 10.1158/1535-7163.mct-13-0338
URL : http://mct.aacrjournals.org/content/12/11/2591.full.pdf

,

D. H. Hamdi, S. Barbieri, C. F. Groetz, J. Legendre, F. Demoor et al., In vitro engineering of human 3D chondrosarcoma: a preclinical model relevant for investigations of radiation quality impact, BMC Cancer, vol.15, p.579, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01315021

J. Nonnekens, M. Van-kranenburg, C. Beerens, M. Suker, M. Doukas et al.,

, Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib, Theranostics, vol.6, pp.1821-1853, 2016.

J. Mclachlan and S. Banerjee, Olaparib for the treatment of epithelial ovarian cancer, Expert Opin Pharmacother, vol.17, pp.995-1003, 2016.

C. Rodriguez-lafrasse and J. Balosso,

, Cancer Radiother J Soc Francaise Radiother Oncol, vol.16, pp.16-24, 2012.

A. Lester, R. Rapkins, S. Nixdorf, M. Khasraw, and K. Mcdonald, Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?, Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex, vol.19, pp.273-281, 2017.

P. M. Lorusso, J. Li, A. Burger, L. K. Heilbrun, E. A. Sausville et al., Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors, Clin Cancer Res Off J Am Assoc Cancer Res, vol.22, pp.3227-3264, 2016.

E. H. Stover, P. A. Konstantinopoulos, U. A. Matulonis, and E. M. Swisher, Biomarkers of Response and Resistance to DNA Repair Targeted Therapies, Clin Cancer Res Off J Am Assoc Cancer Res, vol.22, pp.5651-60, 2016.